Cargando…
Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature
Lenalidomide is indicated in the front-line management of multiple myeloma. More recently, it has been introduced for use in treating other hematologic malignancies. Although the drug is known to cause myelosuppression, there have been rare reports of lenalidomide-associated immune thrombocytopenia...
Autores principales: | Forehand III, William, Ajebo, Germame, Toscano, Michael, Jillella, Anand, Dainer, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676979/ https://www.ncbi.nlm.nih.gov/pubmed/33274089 http://dx.doi.org/10.1155/2020/8825618 |
Ejemplares similares
-
Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
por: Clemmons, Amber, et al.
Publicado: (2021) -
Treatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient Testing Negative for 5q Deletion and JAK2 V617F and MPL W515K/L Mutations
por: Keen, Ryan, et al.
Publicado: (2016) -
Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
por: Win, Hninyee, et al.
Publicado: (2020) -
Epidemiology, Staging, and Management of Multiple Myeloma
por: Padala, Sandeep Anand, et al.
Publicado: (2021) -
Wilson disease associated with immune thrombocytopenia: A case report and review of the literature
por: Ma, Tian-Jiao, et al.
Publicado: (2019)